Page URL: https://www.bionews.org.uk/page_93792

Gene associated with treatment-resistant ovarian cancers identified

24 September 2012
Appeared in BioNews 674

Scientists have discovered a gene called FGF1 which is highly active in aggressive and advanced ovarian cancers.

FGF1 was also found to be active at higher levels in tumours that are resistant to a common form of chemotherapy. Further research is required, but the researchers say that measuring FGF1 expression levels might help doctors decide the most appropriate treatments for patients.

Lead author Dr Gillian Smith, from the University of Dundee, said that the team had identified 'potential ways that ovarian cancer builds resistance to common chemotherapy drugs over time. Our study paves the way for the development of new tests to determine if chemotherapy will work'.

In the study, researchers looked at the activity of ovarian tumours from 187 patients and found that each tumour had a unique gene activity profile. Of all the genes the researchers investigated, FGF1 appeared to have the greatest influence on the way the cancer developed. FGF1 helps tumours grow a blood supply, fuelling their growth.

The researchers also found that FGF1 activity increased after tumour cells had developed resistance to platinum-based chemotherapy drugs like cisplatin and carboplatin. By blocking FGF1 in ovarian cancer cells resistant to platinum drugs, the scientists were able to make them sensitive to chemotherapy again.

Accordingly, Dr Smith said, 'drugs targeting FGF1 could be effective new treatments for a group of women with a type of ovarian cancer that is difficult to treat successfully'.

'Approaches to treatment [for ovarian cancer] are limited,' added Dr Julie Sharp, senior science information manager at Cancer Research UK, which part-funded the research. 'Not all women respond to chemotherapy and there is no way of telling who will benefit most'.

The study is published in the British Journal of Cancer.

SOURCES & REFERENCES
Dundee researchers find chemotherapy efficacy gene
BBC News |  19 September 2012
Gene helps predict which women with ovarian cancer will benefit most from chemotherapy
Cancer Research UK (press release) |  19 September 2012
Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
British Journal of Cancer |  18 September 2012
Ovarian cancer study gets results
Press Association |  19 September 2012
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
16 November 2015 - by Paul Waldron 
Over 100 million genetic changes have been found in a single tumour, according to a new study...
9 September 2013 - by Dr Katie Howe 
Researchers have identified a gene in mice that, if faulty, increases the chances of developing ovarian cancer....
13 August 2012 - by Dr Caroline Hirst 
Chemotherapy can produce a rogue response that eventually leads to tumours becoming resistant to treatment, scientists have found...
23 July 2012 - by Holly Rogers 
A genetic variation could explain why a previously promising class of drugs do not work as multiple sclerosis treatments despite being used successfully in other autoimmune diseases...
9 July 2012 - by Sarah Pritchard 
It is now scientifically feasible to use preimplantation genetic diagnosis (PGD) during IVF to screen embryos for genes associated with high cancer risk, scientists say...
15 August 2011 - by Dr Maria Teresa Esposito 
Scientists have discovered a rare genetic fault that raises a woman's risk of developing ovarian cancer six-fold. It has been hailed as the most important discovery in the field in the last ten years, and offers hope for new treatments...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.